*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · preclinical | PMID 41490200 |
| 2026 | Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians The American journal of sports medicine · preclinical | PMID 41476424 |
| 2025 | Metabolic dysfunction-associated steatotic liver disease in people with HIV Current opinion in HIV and AIDS · preclinical | PMID 40397552 |
| 2021 | Advances in the detection of growth hormone releasing hormone synthetic analogs Drug testing and analysis · preclinical | PMID 34665524 |
| 2021 | A thermosensitive, reactive oxygen species-responsive, MR409-encapsulated hydrogel ameliorates disc degeneration in rats by inhibiting the secretory autophagy pathway Theranostics · preclinical | PMID 33391467 |
| 2019 | An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma Drug testing and analysis · preclinical | PMID 30489688 |
| 2019 | A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS Drug testing and analysis · preclinical | PMID 30938069 |
| 2016 | Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions Substance use & misuse · preclinical | PMID 26771670 |
| 2010 | Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation Drug testing and analysis · preclinical | PMID 21204297 |
| 2009 | Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · preclinical | PMID 19386527 |
| 2006 | Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults The Journal of clinical endocrinology and metabolism · human | PMID 16352683 |
| 2006 | Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse American journal of physiology. Endocrinology and metabolism · preclinical | PMID 16822960 |
| 2006 | Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog The Journal of clinical endocrinology and metabolism · human | PMID 17018654 |
| 2005 | Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology · preclinical | PMID 15817669 |
| 1988 | Response to a growth hormone-releasing hormone analog in heifers treated with recombinant growth hormone Domestic animal endocrinology · preclinical | PMID 3147164 |
CJC-1295 (CJC-1295 (with or without DAC — Drug Affinity Complex)). Synthetic growth-hormone-releasing hormone (GHRH) analogue. Stimulates pituitary GH release. The DAC variant binds albumin for extended half-life; 'no-DAC' (mod GRF 1-29) is short-acting.
Commonly discussed uses: GH axis support (research), body composition, recovery/sleep (anecdotal). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Synthetic growth-hormone-releasing hormone (GHRH) analogue. Stimulates pituitary GH release. The DAC variant binds albumin for extended half-life; 'no-DAC' (mod GRF 1-29) is short-acting.
Reported considerations: anecdotal: injection-site reaction, flushing, head-rush, water retention. There is both human and animal/preclinical research, though the depth and quality vary by indication. WADA-prohibited. Not approved for human therapeutic use. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 100mcg (no-DAC), typical 100-200mcg per dose (no-DAC, 1-3x/day), high DAC 2mg/week. Administration: subcutaneous. Half-life: no-DAC: ~30 min; DAC: ~6-8 days.
Australian status: Not ARTG-registered; prescription-only/research. WADA-prohibited. Not approved for human therapeutic use. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: 2ml BAC water per 2-5mg vial; storage: reconstituted refrigerated, ~few weeks.
Commonly discussed combinations (anecdotal for unapproved compounds): CJC-1295 + Ipamorelin (GH-axis stack). Stacking increases interaction/safety uncertainty.